Agree. Not disputing it completely, but it always makes me feel a bit uneasy whenever it's blurted out as a selling point for bisantrene. Obviously I'm not trying to downplay the potential positive impact of bisantrene and the role it may have played, but there are so many genetic factors that could have also influenced their outcome to that degree, they were very lucky indeed. How bisantrene worked for the majority is what I'm more interested in (and would tilt the risk toward)
MST valuation of RAC, page-178
-
- There are more pages in this discussion • 119 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.000(0.00%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.95 | $1.95 | $1.84 | $647.3K | 344.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3300 | $1.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.94 | 5654 | 2 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |